Does aficamten reduce LVOT gradients and improve biomarkers and symptoms in patients with obstructive hypertrophic cardiomyopathy?
Aficamten, a sarcomere-targeted therapy, effectively reduces LVOT gradients and improves symptoms in patients with obstructive hypertrophic cardiomyopathy.
Aficamten resulted in substantial reductions in LVOT gradients with most patients experiencing improvement in biomarkers and symptoms. These results highlight the potential of sarcomere-targeted therapy for treatment of oHCM.
Maron et al. (Sun,) studied this question.